Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Amgen, Sandoz Seek Rehearing On Biosimilar Court Case

This article was originally published in SRA

Executive Summary

Amgen and Sandoz have both filed petitions asking the US Court of Appeals for the Federal Circuit to rehear a panel ruling interpreting the provisions of the biosimilars statute. Amgen argues against the finding that the information exchange process in the law is optional, while Sandoz objects to the panel’s decision that biosimilar sponsors must wait until Food and Drug Administration approval to provide notice of commercial launch1,2.

Advertisement
Advertisement
UsernamePublicRestriction

Register